Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jennings Nestor

Critical Care Medicine Charleston, SC Medical Doctor

NPI 1972778652 CMS profile 818201

9330 Medical Plaza Dr, Charleston, SC 29406

Open in the dashboard

General payments

$5,408

264 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennings Nestor of Charleston, SC is reported in the CMS Open Payments database as having received $5,408 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47 3
2024 General $1,587 67
2023 General $1,478 74
2022 General $1,757 89
2021 General $449 25
2020 General $11 1
2019 General $77 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennings Nestor
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Jennings Nestor were reported at $47. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Jennings Nestor Critical Care Medicine median Middle half National median
2019 $77 $149 $51–$535 $163
2020 $11 $110 $30–$325 $114
2021 $449 $125 $34–$403 $132
2022 $1,757 $157 $49–$582 $149
2023 $1,478 $162 $56–$621 $160
2024 $1,587 $168 $53–$634 $164
2025 $47 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $955 54 payments
  2. AstraZeneca Pharmaceuticals LP $792 38 payments
  3. Insmed, Inc. $548 19 payments
  4. Electromed, Inc. $383 21 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $294 13 payments
  6. Genzyme Corporation $258 11 payments
  7. Amgen Inc. $245 12 payments
  8. Grifols USA, LLC $243 12 payments
  9. United Therapeutics Corporation $182 7 payments
  10. Baxter Healthcare $167 8 payments
  11. Other $1,340 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,391 263 payments
  2. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $719 40 payments
  2. BREZTRI $564 23 payments
  3. Arikayce $526 18 payments
  4. SMARTVEST $383 21 payments
  5. DUPIXENT $258 11 payments
  6. TEZSPIRE Inflammation $245 12 payments
  7. FASENRA $237 8 payments
  8. AIRSUPRA $207 5 payments
  9. TEZSPIRE Respiratory $192 4 payments
  10. NUCALA $182 11 payments
  11. Other $2,820 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

2,665

Median for Pulmonary Disease: 936

Drug cost

$940,746

Median for Pulmonary Disease: $487,987

Branded share of claims

56.7%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 609 $499,024
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 198 $166,576
Dupixent Pen Dupilumab Brand 12 $46,000
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 70 $44,986
Nucala Mepolizumab Brand 11 $38,118
Breo Ellipta Fluticasone/Vilanterol Brand 60 $32,644
Spiriva Respimat Tiotropium Bromide Brand 43 $22,749
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 37 $22,596
Albuterol Sulfate Hfa Albuterol Sulfate Brand 301 $9,451
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 14 $7,251

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$117,085

Medicare's payments for the services billed

Medicare patients

578

Average age 75

Services billed

1,794

309 women, 269 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 66%
Arthritis 53%
Ischemic heart disease 43%
Heart failure 37%
Atrial fibrillation 34%
Diabetes 33%
Chronic kidney disease 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arikayce
  • Insmed, Inc. $158
$158 — —
DUPIXENT
  • GENZYME CORPORATION $88
  • Regeneron Healthcare Solutions, Inc. $61
$150 12 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $141
$141 609 —
TYVASO
  • United Therapeutics Corporation $116
$116 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $105
$105 198 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record